Literature DB >> 33713668

Pharmacology of lacosamide: From its molecular mechanisms and pharmacokinetics to future therapeutic applications.

Andreia Carona1, Joana Bicker1, Rui Silva1, Carla Fonseca1, Amílcar Falcão1, Ana Fortuna2.   

Abstract

Epilepsy is one of the most common brain disorders, affecting more than 50 million people worldwide. Although its treatment is currently symptomatic, the last generation of anti-seizure drugs is characterized by better pharmacokinetic profiles, efficacy, tolerability and safety. Lacosamide is a third-generation anti-seizure drug that stands out due to its good efficacy and safety profile. It is used with effectiveness in the treatment of partial-onset seizures with or without secondary generalization, primary generalized tonic-clonic seizures and off-label in status epilepticus. Despite scarcely performed until today, therapeutic drug monitoring of lacosamide is proving to be advantageous by allowing the control of inter and intra-individual variability and promoting a successful personalized therapy, particularly in special populations. Herein, the pharmacology, pharmacokinetics, and clinical data of lacosamide were reviewed, giving special emphasis to the latest molecular investigations underlying its mechanism of action and therapeutic applications in pathologies besides epilepsy. In addition, the pharmacokinetic characteristics of lacosamide were updated, as well as current literature concerning the high pharmacokinetic variability observed in special patient populations and that must be considered during treatment individualization.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Epilepsy; Individual variability; Lacosamide; Neuropathic pain; Pharmacokinetics; Pharmacology

Mesh:

Substances:

Year:  2021        PMID: 33713668     DOI: 10.1016/j.lfs.2021.119342

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  4 in total

1.  Lacosamide Inhibition of NaV1.7 Channels Depends on its Interaction With the Voltage Sensor Domain and the Channel Pore.

Authors:  Julie I R Labau; Matthew Alsaloum; Mark Estacion; Brian Tanaka; Fadia B Dib-Hajj; Giuseppe Lauria; Hubert J M Smeets; Catharina G Faber; Sulayman Dib-Hajj; Stephen G Waxman
Journal:  Front Pharmacol       Date:  2021-12-21       Impact factor: 5.810

2.  Evidence for Inhibitory Perturbations on the Amplitude, Gating, and Hysteresis of A-Type Potassium Current, Produced by Lacosamide, a Functionalized Amino Acid with Anticonvulsant Properties.

Authors:  Hsin-Yen Cho; Tzu-Hsien Chuang; Sheng-Nan Wu
Journal:  Int J Mol Sci       Date:  2022-01-21       Impact factor: 5.923

3.  Plasma lacosamide monitoring in children with epilepsy: Focus on reference therapeutic range and influencing factors.

Authors:  Yue Li; Hong-Li Guo; Yuan-Yuan Zhang; Na Dong; Ya-Hui Hu; Jing Chen; Xiao-Peng Lu; Feng Chen
Journal:  Front Pediatr       Date:  2022-09-07       Impact factor: 3.569

4.  A 5-Year Study of Lithium and Valproic Acid Drug Monitoring in Patients with Bipolar Disorders in an Italian Clinical Center.

Authors:  Marco Carli; Eleonora Risaliti; Mena Francomano; Shivakumar Kolachalam; Biancamaria Longoni; Guido Bocci; Roberto Maggio; Marco Scarselli
Journal:  Pharmaceuticals (Basel)       Date:  2022-01-17
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.